Site-directed mutagenesis of human pancreatic secretory trypsin inhibitor

J Biochem. 1989 Dec;106(6):1059-63. doi: 10.1093/oxfordjournals.jbchem.a122964.

Abstract

Arg-42 or Lys-43 or Arg-44 of human pancreatic secretory trypsin inhibitor (PSTI) was replaced by Thr or Ser by site-directed mutagenesis, and the inactivation rates of the mutants after mixing with human trypsin were compared with that of the natural form. The inactivation rate decreased for one mutant (Arg-44----Ser), whereas no change was observed for another (Arg-42----Thr) and an increase was observed for a third (Lys-43----Thr). Kinetic studies on the interactions between human trypsin and synthetic peptides, comprising the regions of Phe39-Ser47 of the respective PSTI species, showed that human trypsin cleaved the Arg42-Lys43 bond preferentially to the Arg44-Gln45 bond. However, it is cleavage of the latter bond that is thought to cause inactivation of human PSTI. These results suggest that the Arg44-Gln45 bond of human PSTI is responsible for its inhibitory activity, and inactivation of human PSTI is probably caused by deletion of the dipeptide Lys43-Arg44.

MeSH terms

  • Amino Acids
  • Humans
  • Hydrolysis
  • Kinetics
  • Molecular Weight
  • Mutation
  • Oligonucleotides / pharmacology
  • Peptides / metabolism
  • Trypsin / metabolism
  • Trypsin Inhibitor, Kazal Pancreatic / genetics*
  • Trypsin Inhibitor, Kazal Pancreatic / metabolism
  • Trypsin Inhibitors / genetics*

Substances

  • Amino Acids
  • Oligonucleotides
  • Peptides
  • Trypsin Inhibitors
  • Trypsin Inhibitor, Kazal Pancreatic
  • Trypsin